Purpose: This research observed the efficacy and safety of soft tissue expansion combined with recombinant human epidermal growth factor (rhEGF) in repairing second-degree scald scars. Methods: This study conducted a prospective, single-blind, randomized controlled trial. Eighty-four patients with deep second-degree scald scars were evenly divided into the control and observation groups. The control group was treated with soft tissue expansion, and the observation group was additionally treated with rhEGF. The skin expansion and wound healing times were compared. The changes in wound exudate and inflammation around the wound were observed after first-stage surgery. The hydroxyproline (OHP) and collagen I/III ratios were compared during the second stage of surgery.The complications and repair effects during treatment were evaluated. Results: The observation group exhibited lower expansion time, immediate retraction rate, and wound healing time, higher skin expansion rate, higher wound exudate score and inflammation score, higher OHP, lower collagen I/III, lower complication rate, and higher total effective rate than the control group (all P < 0.05). Conclusion Skin soft tissue expansion combined with rhEGF is more effective in repairing second-degree scald scars, which can effectively increase skin expansion area and reduce wound infection and complications.

Objective:To explore the clinical efficacy of Bulleyaconitine A combined with pregabalin in the treatment of herpes zoster neuralgia (HZN), and its effects on serum neuropeptide, interleukin-17 (IL-17), CXC chemokine ligand 10 (CXCL10), and nuclear factor-κB (NF-κB) levels.Methods:A total of 114 HZN patients admitted to the Second Hospital of Tianjin Medical University from January 2021 to December 2022 were selected and divided into observation group ( n=57) and control group ( n=57) by random number table method. The control group was treated with oral pregabalin capsules, and the observation group was treated with Bulleyaconitine A on the basis of the control group for 4 weeks. The clinical efficacy of the two groups was observed. The Visual Analogue Scale (VAS) score for pain, total score of Pittsburgh Sleep Quality Index (PSQI), total score of The MOS 36 Item Short form Health Survey (SF-36), as well as serum neuropeptide [substance P (SP), neuropeptide Y (NPY), β-endorphin (β-EP)] and IL-17, CXCL10, NF-κB levels were compared between the two groups before and after treatment. The occurrence of adverse reactions in the two groups was recorded. Results:The total effective rate of the observation group [82.46%(47/57)] was significantly higher than that of the control group [64.91%(37/57), P<0.05]. Before treatment, there were no significant differences in VAS score, total PSQI score, and total SF-36 score between the two groups (all P>0.05); after treatment, the VAS score and total PSQI score of both groups were significantly decreased (all P<0.05), the total SF-36 score was significantly increased (all P<0.05), and the above indicators in the observation group were better than those in the control group (all P<0.05). Before treatment, there were no significant differences in serum SP, NPY, and β-EP levels between the two groups (all P>0.05); after treatment, serum SP and NPY levels in both groups were significantly decreased (all P<0.05), serum β-EP levels were significantly increased (all P<0.05), and serum SP and NPY levels in the observation group were lower than those in the control group (all P<0.05), serum β-EP levels were higher than those in the control group ( P<0.05). Before treatment, there were no significant differences in serum IL-17, CXCL10, and NF-κB levels between the two groups (all P>0.05); after treatment, serum IL-17, CXCL10, and NF-κB levels in both groups were significantly decreased (all P<0.05), and serum IL-17, CXCL10, and NF-κB levels in the observation group were lower than those in the control group (all P<0.05). There was no significant difference in the adverse reaction rate between the observation group [7.02%(4/57)] and the control group [12.28%(7/57)] ( P>0.05). Conclusions:Bulleyaconitine A combined with pregabalin has good efficacy and safety in the treatment of HZN, which can effectively reduce the degree of neuropathic pain and improve sleep and quality of life. Its mechanism may be related to further regulating the level of neuropeptide and inhibiting the inflammatory state in the body.

Objective To explore the value of 3D and 2D radiomics features models based on multiparameter MRI in predicting Ki-67 expression(with 14%and 20%as the critical values,respectively)in breast cancer.Methods The MRI images of 147 patients with pathologically confirmed Luminal breast cancer were analyzed retrospectively.The patients were randomly divided into training set and test set according to the ratio of 7︰3.The 3D and 2D radiomics features of intratumor and peritumor were extracted from diffusion weighted imaging(DWI),dynamic contrast enhancement(DCE)mask(S0)and DCE phase 3(S3)images.Then the models were constructed by multiple pipeline combinations of three feature normalization methods,two feature dimensionality reduction methods,four feature selection methods,and ten classifiers.The receiver operating characteristic(ROC)curve and the area under the curve(AUC)were used to evaluate the prediction performance of the models in order to select the best 3D and 2D single parame-ter(DWI,S0,S3)and multiparameter combination(S0+S3,S0+DWI,S3+DWI,S0+S3+DWI)models.Finally,the differ-ences between the models were compared by De Long test.Results With 14%as the critical value,the AUC of 3D and 2D models in the training set were 0.726-0.824 and 0.707-0.835,respectively,and those in the test set were 0.724-0.82 and 0.701-0.805.With 20%as the critical value,the AUC of 3D and 2D models in the training set were 0.743-0.868 and 0.793-0.881,respectively,and those in the test set were 0.738-0.853 and 0.743-0.814.There was no significant statistical difference between 3D and 2D models with the same parameter in the two critical values standards.Conclusion The multiparameter MRI-based radiomics models can bet-ter predict the expression of Ki-67 in breast cancer,and the models based on intratumor and peritumor 3D and 2D features have the same prediction efficiency.

Emerging evidence suggests that dysbiosis of the gut microbiota is associated with the pathogenesis of Parkinson's disease (PD), a prevalent neurodegenerative disorder. The microbiota-gut-brain axis plays a crucial role in the development and progression of PD, and numerous studies have demonstrated the potential therapeutic benefits of modulations in the intestinal microbiota. This review provides insights into the characterization of the gut microbiota in patients with PD and highlights associations with clinical symptoms and underlying mechanisms. The discussion underscores the increased influence of the gut microbiota in the pathogenesis of PD. While the relationship is not fully elucidated, existing research demonstrates a strong correlation between changes in the composition of gut microbiota and disease development, and further investigation is warranted to explain the specific underlying mechanisms.
Humans ; Parkinson Disease/microbiology* ; Gastrointestinal Microbiome/physiology* ; Dysbiosis/microbiology*

Purpose: This research observed the efficacy and safety of soft tissue expansion combined with recombinant human epidermal growth factor (rhEGF) in repairing second-degree scald scars. Methods: This study conducted a prospective, single-blind, randomized controlled trial. Eighty-four patients with deep second-degree scald scars were evenly divided into the control and observation groups. The control group was treated with soft tissue expansion, and the observation group was additionally treated with rhEGF. The skin expansion and wound healing times were compared. The changes in wound exudate and inflammation around the wound were observed after first-stage surgery. The hydroxyproline (OHP) and collagen I/III ratios were compared during the second stage of surgery.The complications and repair effects during treatment were evaluated. Results: The observation group exhibited lower expansion time, immediate retraction rate, and wound healing time, higher skin expansion rate, higher wound exudate score and inflammation score, higher OHP, lower collagen I/III, lower complication rate, and higher total effective rate than the control group (all P < 0.05). Conclusion Skin soft tissue expansion combined with rhEGF is more effective in repairing second-degree scald scars, which can effectively increase skin expansion area and reduce wound infection and complications.

Purpose: This research observed the efficacy and safety of soft tissue expansion combined with recombinant human epidermal growth factor (rhEGF) in repairing second-degree scald scars. Methods: This study conducted a prospective, single-blind, randomized controlled trial. Eighty-four patients with deep second-degree scald scars were evenly divided into the control and observation groups. The control group was treated with soft tissue expansion, and the observation group was additionally treated with rhEGF. The skin expansion and wound healing times were compared. The changes in wound exudate and inflammation around the wound were observed after first-stage surgery. The hydroxyproline (OHP) and collagen I/III ratios were compared during the second stage of surgery.The complications and repair effects during treatment were evaluated. Results: The observation group exhibited lower expansion time, immediate retraction rate, and wound healing time, higher skin expansion rate, higher wound exudate score and inflammation score, higher OHP, lower collagen I/III, lower complication rate, and higher total effective rate than the control group (all P < 0.05). Conclusion Skin soft tissue expansion combined with rhEGF is more effective in repairing second-degree scald scars, which can effectively increase skin expansion area and reduce wound infection and complications.

Oral cancer is a malignant tumor with poor incidence and prognosis among primary head and neck tumors, and postoperative patients are often combined with surgical scar, dysphagia, mastication difficulties, and speech dysfunction, which bring heavy physiological and psychological burdens to the patients, and make their reintegration into the society after cancer generally poorly adapted. Factors such as patients′ role transition, swallowing function, life and social changes during treatment will affect their psychosocial adaptive function. The enhancement of psychosocial adaptive ability helps to stimulate patients′ intrinsic potential, improve their psychological state, and enable them to adapt to the changes brought by the disease, thus promoting their physical and mental health. In this paper, we review domestic and international nursing interventions such as perioperative nursing interventions, continuity nursing interventions, and cosmetic nursing to effectively improve patients′postoperative psychosocial adaptations, and provide a theoretical basis for the future development of a scientific and effective intervention program for psychosocial adaptations in oral cancer.

Objective:To investigate the efficacy of radiotherapy in patients with advanced esophageal cancer receiving first-line chemoimmunotherapy.Methods:A retrospective analysis was conducted on the data of 137 patients with Stage Ⅳ esophageal squamous cell carcinoma (ESCC) treated at our hospital from January 2018 to May 2023. These patients were divided into two groups: a group treated with first-line chemoimmunotherapy combined with radiotherapy (chemoimmunotherapy + radiotherapy group, n = 43) and a group treated with only chemoimmunotherapy ( n = 94). Inverse probability of treatment weighting (IPTW) was applied to balance baseline characteristics between the groups. With overall survival (OS) and progression-free survival (PFS) as study endpoints, the survival data were analyzed using the Kaplan-Meier method, the log-rank test, and the Cox regression method. Results:Before calibration, the chemoimmunotherapy + radiotherapy group significantly outperformed the sole chemoimmunotherapy group in median PFS (13.6 months vs. 7.0 months; HR: 0.501, 95% CI: 0.309-0.811, P = 0.005). After calibration using the COX proportional-hazards model for age, gender, Eastern Cooperative Oncology Group (ECOG) performance status, smoking history, T/N/M stage, and tumor location, the chemoimmunotherapy + radiotherapy group still had significant advantages in PFS (14.7 months vs. 7.0 months; HR: 0.441, 95% CI: 0.261-0.745, P = 0.002). IPTW analysis further confirmed this trend (13.9 months vs. 7.0 months; HR: 0.492, 95% CI: 0.304-0.795, P < 0.001). Specifically, the median OS of the chemoimmunotherapy + radiotherapy group demonstrated significant improvement in all analyses: pre-calibration (29.5 months vs. 18.0 months; HR: 0.507, 95% CI: 0.297-0.867, P = 0.013), after calibration using the Cox model (27.5 months vs. 16.7 months; HR: 0.470, 95% CI: 0.266-0.830, P = 0.009), and after calibration using IPTW (29.5 months vs. 16.9 months; HR: 0.448, 95% CI: 0.262-0.764, P < 0.001). Conclusions:The combination of radiotherapy and first-line chemoimmunotherapy can significantly improve survival outcomes of patients with advanced ESCC, suggesting its potential as a standard treatment strategy.

Objective:To construct a comprehensive evaluation index system for the clinical usability of clinical nursing information systems from the perspective of nurses, providing a basis for the improvement of clinical nursing information systems.Methods:Using an integrated model, this study employed both quantitative research through systematic reviews and qualitative research via Meta-integration methods to preliminarily construct the index system. Expert consultations were conducted to modify and refine the index system. The final version of the evaluation index system for clinical nursing information systems' usability, based on the users' perspective, was established.Results:A total of 20 experts in the field of nursing information were included in this study. The response rates for the two rounds of expert consultation were 100% and 85%, respectively. The authority coefficients were 0.878 and 0.886, and the Kendall harmony coefficients for the importance and rationality scores of the indices in the two rounds of expert consultation ranged from 0.182 to 0.231 ( P<0.05). The final evaluation index system included four primary indicators, 10 secondary indicators, and 37 tertiary indicators. Conclusions:The developed evaluation index system for the clinical usability of clinical nursing information systems from the user's perspective is scientific, reliable, advanced, and practical. It effectively reflects the key aspects of nurses' evaluations of clinical nursing information systems and provides a foundation for promoting the high-quality and sustainable development of clinical nursing information systems.

Objective:To investigate the efficacy of radiotherapy in patients with advanced esophageal cancer receiving first-line chemoimmunotherapy.Methods:A retrospective analysis was conducted on the data of 137 patients with Stage Ⅳ esophageal squamous cell carcinoma (ESCC) treated at our hospital from January 2018 to May 2023. These patients were divided into two groups: a group treated with first-line chemoimmunotherapy combined with radiotherapy (chemoimmunotherapy + radiotherapy group, n = 43) and a group treated with only chemoimmunotherapy ( n = 94). Inverse probability of treatment weighting (IPTW) was applied to balance baseline characteristics between the groups. With overall survival (OS) and progression-free survival (PFS) as study endpoints, the survival data were analyzed using the Kaplan-Meier method, the log-rank test, and the Cox regression method. Results:Before calibration, the chemoimmunotherapy + radiotherapy group significantly outperformed the sole chemoimmunotherapy group in median PFS (13.6 months vs. 7.0 months; HR: 0.501, 95% CI: 0.309-0.811, P = 0.005). After calibration using the COX proportional-hazards model for age, gender, Eastern Cooperative Oncology Group (ECOG) performance status, smoking history, T/N/M stage, and tumor location, the chemoimmunotherapy + radiotherapy group still had significant advantages in PFS (14.7 months vs. 7.0 months; HR: 0.441, 95% CI: 0.261-0.745, P = 0.002). IPTW analysis further confirmed this trend (13.9 months vs. 7.0 months; HR: 0.492, 95% CI: 0.304-0.795, P < 0.001). Specifically, the median OS of the chemoimmunotherapy + radiotherapy group demonstrated significant improvement in all analyses: pre-calibration (29.5 months vs. 18.0 months; HR: 0.507, 95% CI: 0.297-0.867, P = 0.013), after calibration using the Cox model (27.5 months vs. 16.7 months; HR: 0.470, 95% CI: 0.266-0.830, P = 0.009), and after calibration using IPTW (29.5 months vs. 16.9 months; HR: 0.448, 95% CI: 0.262-0.764, P < 0.001). Conclusions:The combination of radiotherapy and first-line chemoimmunotherapy can significantly improve survival outcomes of patients with advanced ESCC, suggesting its potential as a standard treatment strategy.